Southeast Asia Roundup: Picinaf Recall In Philippines, Halal Vaccines Set To Surge
This article was originally published in PharmAsia News
Executive Summary
The Philippines orders a recall of the Picinaf pulmonary tuberculosis drug of JM Tolman Laboratories because of under-dosing problems and experts say the global Muslim halal market for vaccines is forecast to be worth $1.1 billion, or 3% of the products expected to be on the vaccine market by 2030.